MX2020005907A - Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma. - Google Patents
Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma.Info
- Publication number
- MX2020005907A MX2020005907A MX2020005907A MX2020005907A MX2020005907A MX 2020005907 A MX2020005907 A MX 2020005907A MX 2020005907 A MX2020005907 A MX 2020005907A MX 2020005907 A MX2020005907 A MX 2020005907A MX 2020005907 A MX2020005907 A MX 2020005907A
- Authority
- MX
- Mexico
- Prior art keywords
- serum
- free media
- methods
- cells
- culturing cells
- Prior art date
Links
- 239000004017 serum-free culture medium Substances 0.000 title abstract 5
- 238000012258 culturing Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 4
- 230000003213 activating effect Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 230000002463 transducing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0031—Serum-free culture media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/99—Serum-free medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporciona en la presente un medio libre de suero para cultivar, tal como cultivar, preparar y/o producir células, tal como células inmunes, tal como células genéticamente modificadas. También se proporciona un medio basal líquido y complementos congelados que se pueden usar para producir el medio libre de suero. Las modalidades proporcionadas incluyen métodos para producir el medio libre de suero y métodos para cultivar células, tal como activar, transducir, cultivar o expandir células, en presencia del medio libre de suero.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762596766P | 2017-12-08 | 2017-12-08 | |
PCT/US2018/064627 WO2019113556A1 (en) | 2017-12-08 | 2018-12-07 | Serum-free media formulation for culturing cells and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020005907A true MX2020005907A (es) | 2020-10-19 |
Family
ID=64902479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020005907A MX2020005907A (es) | 2017-12-08 | 2018-12-07 | Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210207080A1 (es) |
EP (1) | EP3720949A1 (es) |
JP (2) | JP7433230B2 (es) |
KR (1) | KR20200108277A (es) |
CN (1) | CN112041430A (es) |
AU (1) | AU2018379091A1 (es) |
BR (1) | BR112020011144A2 (es) |
CA (1) | CA3084444A1 (es) |
EA (1) | EA202091407A1 (es) |
IL (1) | IL275076A (es) |
MA (1) | MA51105A (es) |
MX (1) | MX2020005907A (es) |
SG (1) | SG11202005228YA (es) |
WO (1) | WO2019113556A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110499291B (zh) * | 2018-05-16 | 2023-11-24 | 上海赛比曼生物科技有限公司 | 无血清培养制备嵌合抗原受体t细胞的方法 |
US20220267726A1 (en) * | 2019-07-18 | 2022-08-25 | Gpb Scientific, Inc. | Ordered processing of blood products to produce therapeutically active cells |
US20240182920A1 (en) * | 2020-01-22 | 2024-06-06 | Carsgen Therapeutics Co., Ltd. | Method for transducing cells with viral vector |
CN112920995A (zh) * | 2021-03-31 | 2021-06-08 | 赵峻岭 | 一种间充质干细胞培养血清加油包及其应用 |
CN114250198A (zh) * | 2021-08-13 | 2022-03-29 | 北京肿瘤医院(北京大学肿瘤医院) | 一种增强免疫细胞抗肿瘤效果的方法 |
CN115044548B (zh) * | 2022-08-11 | 2022-10-25 | 北京原生元生物科技有限公司 | 一种无血清培养基及其应用 |
WO2024124132A1 (en) | 2022-12-09 | 2024-06-13 | Juno Therapeutics, Inc. | Machine learning methods for predicting cell phenotype using holographic imaging |
CN116179475B (zh) * | 2023-04-23 | 2023-07-28 | 北京国卫生物科技有限公司 | 一种人脐静脉血管内皮细胞的分离培养方法 |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
IN165717B (es) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
WO1990007380A2 (en) | 1988-12-28 | 1990-07-12 | Stefan Miltenyi | Methods and materials for high gradient magnetic separation of biological materials |
US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
WO1996013593A2 (en) | 1994-10-26 | 1996-05-09 | Procept, Inc. | Soluble single chain t cell receptors |
WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
US20020150914A1 (en) | 1995-06-30 | 2002-10-17 | Kobenhavns Universitet | Recombinant antibodies from a phage display library, directed against a peptide-MHC complex |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
US6451995B1 (en) | 1996-03-20 | 2002-09-17 | Sloan-Kettering Institute For Cancer Research | Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods |
ATE186235T1 (de) | 1996-04-24 | 1999-11-15 | Claude Fell | Zelltrennungsvorrichtung für biologische flüssigkeiten wie blut |
AU742650B2 (en) | 1997-10-02 | 2002-01-10 | Altor Bioscience Corporation | Soluble single-chain T-cell receptor proteins |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
DE69900468T2 (de) | 1998-05-19 | 2002-07-18 | Avidex Ltd | Löslicher t-zell rezeptor |
CA2343156A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
EP1144026B1 (en) | 1998-12-24 | 2004-07-28 | Biosafe S.A. | Blood separation system particularly for concentrating hematopoietic stem cells |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
WO2002077029A2 (en) | 2000-11-07 | 2002-10-03 | City Of Hope | Cd19-specific redirected immune cells |
US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
ES2239246T3 (es) | 2001-08-31 | 2005-09-16 | Avidex Limited | Receptor soluble de celulas t. |
US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
WO2003070752A2 (en) | 2002-02-20 | 2003-08-28 | Dyax Corporation | Mhc-peptide complex binding ligands |
US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
AU2005235811B2 (en) | 2004-02-06 | 2011-11-03 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
WO2005116072A2 (en) | 2004-05-27 | 2005-12-08 | Weidanz Jon A | Antibodies as t cell receptor mimics, methods of production and uses thereof |
US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
US20090226474A1 (en) | 2004-05-27 | 2009-09-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
DE602005022595D1 (de) | 2004-06-29 | 2010-09-09 | Immunocore Ltd | Einen modifizierten t-zellen-rezeptor exprimierende zellen |
US7829673B2 (en) | 2005-03-23 | 2010-11-09 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
RU2410125C2 (ru) | 2005-03-23 | 2011-01-27 | Биосейф С.А. | Комплексная система для сбора, обработки и трансплантации клеточных субпопуляций, включая зрелые стволовые клетки, для регенеративной медицины |
WO2008035631A1 (fr) | 2006-09-20 | 2008-03-27 | Kyowa Hakko Kogyo Co., Ltd. | Procédé de production d'une substance |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
DK2141997T3 (da) | 2007-03-30 | 2013-02-11 | Sloan Kettering Inst Cancer | Konstitutiv ekspression af co-stimulatoriske ligander på adoptivt overførte t-lymfocytter |
ATE528077T1 (de) | 2007-12-07 | 2011-10-15 | Miltenyi Biotec Gmbh | Zentrifuge zur trennung einer probe in mindestens zwei komponenten |
US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
EP2222861B1 (en) | 2007-12-11 | 2017-12-06 | The University of North Carolina At Chapel Hill | Polypurine tract modified retroviral vectors |
WO2009080829A1 (en) | 2007-12-26 | 2009-07-02 | Biotest Ag | Agents targeting cd138 and uses thereof |
US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
DK3006459T3 (da) | 2008-08-26 | 2021-12-06 | Hope City | Fremgangsmåde og sammensætninger til forbedring af t-cellers antitumoreffektorfunktion |
JP2012507555A (ja) | 2008-10-31 | 2012-03-29 | アボット バイオセラピューティクス コーポレイション | 稀少疾患の治療における抗cs1抗体の使用 |
HUE029619T4 (en) | 2009-03-10 | 2017-07-28 | Biogen Ma Inc | Anti-bcma antibodies |
JP6132548B2 (ja) | 2009-04-01 | 2017-05-24 | ジェネンテック, インコーポレイテッド | 抗FcRH5抗体および免疫接合体および使用方法 |
WO2011044186A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
AU2010315243B2 (en) | 2009-11-03 | 2016-08-25 | City Of Hope | Truncated epidermal growth factor receptor (EGFRt) for transduced T cell selection |
ES2700966T3 (es) | 2010-12-09 | 2019-02-20 | Univ Pennsylvania | Utilización de linfocitos T modificados con receptores de antígeno quiméricos para tratar el cáncer |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
CN103502438A (zh) | 2011-03-23 | 2014-01-08 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
SG193956A1 (en) | 2011-04-01 | 2013-11-29 | Sloan Kettering Inst Cancer | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 |
US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
ES2687954T3 (es) | 2011-11-11 | 2018-10-30 | Fred Hutchinson Cancer Research Center | Inmunoterapia de linfocitos T dirigidos a ciclina A1 contra el cáncer |
US8497124B2 (en) * | 2011-12-05 | 2013-07-30 | Factor Bioscience Inc. | Methods and products for reprogramming cells to a less differentiated state |
AU2013221672B2 (en) | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
MX361760B (es) | 2012-05-03 | 2018-12-17 | Hutchinson Fred Cancer Res | Receptores de celulas t con afinidad aumentada y metodos para hacer los mismos. |
SI2884999T1 (sl) | 2012-08-20 | 2021-05-31 | Fred Hutchinson Cancer Research Center | Metoda in sestavki za celično imunoterapijo |
NZ746914A (en) | 2012-10-02 | 2020-03-27 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
US9405601B2 (en) | 2012-12-20 | 2016-08-02 | Mitsubishi Electric Corporation | In-vehicle apparatus and program |
TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
TWI725931B (zh) | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗fcrh5抗體 |
US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
HUE052573T2 (hu) | 2013-12-20 | 2021-05-28 | Hutchinson Fred Cancer Res | Jelölt kiméra effektormolekulák és receptoraik |
BR112016024579A2 (pt) | 2014-04-23 | 2017-10-10 | Juno Therapeutics Inc | métodos para isolamento, cultura e engenharia genética de populações de célula imune para terapia adotiva |
DK3166968T3 (da) | 2014-05-02 | 2021-12-06 | Univ Pennsylvania | Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler |
TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
RS60685B1 (sr) | 2014-11-05 | 2020-09-30 | Juno Therapeutics Inc | Postupci za transdukciju i obradu ćelija |
CN104450614B (zh) * | 2014-12-05 | 2017-07-07 | 上海安集协康生物技术股份有限公司 | 一种无动物蛋白源的免疫细胞无血清培养基及其使用方法 |
AU2015357533B2 (en) | 2014-12-05 | 2021-10-07 | Eureka Therapeutics, Inc. | Antibodies targeting B-cell maturation antigen and methods of use |
IL252617B (en) | 2014-12-05 | 2022-09-01 | Memorial Sloan Kettering Cancer Center | All B-cell maturation antigen-directed chimeric antigen receptors and their uses |
CN118271463A (zh) | 2014-12-05 | 2024-07-02 | 纪念斯隆-凯特琳癌症中心 | 靶向g-蛋白偶联受体的嵌合抗原受体及其用途 |
CN107206077B (zh) | 2014-12-05 | 2021-06-08 | 纪念斯隆-凯特琳癌症中心 | 靶向g-蛋白偶联受体的抗体和使用方法 |
JP7034934B2 (ja) | 2016-04-01 | 2022-03-14 | カイト ファーマ インコーポレイテッド | キメラ抗原及びt細胞受容体、並びに使用方法 |
CN106754670B (zh) * | 2016-11-30 | 2020-02-14 | 湖南省生宝生物科技有限公司 | 一种间充质干细胞无血清培养基及其配制方法和应用 |
CN106834218B (zh) * | 2017-01-06 | 2021-03-02 | 沈阳艾米奥生物工程技术研发中心有限公司 | 人羊膜上皮干细胞无血清培养基及其培养方法 |
PL3372670T3 (pl) * | 2017-03-09 | 2019-08-30 | Evonik Technochemie Gmbh | Pożywki hodowlane zawierające dipeptydy n-acylo-x-glutaminy |
-
2018
- 2018-12-07 EP EP18829646.1A patent/EP3720949A1/en active Pending
- 2018-12-07 JP JP2020530976A patent/JP7433230B2/ja active Active
- 2018-12-07 CA CA3084444A patent/CA3084444A1/en active Pending
- 2018-12-07 MA MA051105A patent/MA51105A/fr unknown
- 2018-12-07 BR BR112020011144-9A patent/BR112020011144A2/pt unknown
- 2018-12-07 AU AU2018379091A patent/AU2018379091A1/en active Pending
- 2018-12-07 KR KR1020207019667A patent/KR20200108277A/ko unknown
- 2018-12-07 SG SG11202005228YA patent/SG11202005228YA/en unknown
- 2018-12-07 CN CN201880088464.9A patent/CN112041430A/zh active Pending
- 2018-12-07 WO PCT/US2018/064627 patent/WO2019113556A1/en unknown
- 2018-12-07 US US16/770,052 patent/US20210207080A1/en active Pending
- 2018-12-07 EA EA202091407A patent/EA202091407A1/ru unknown
- 2018-12-07 MX MX2020005907A patent/MX2020005907A/es unknown
-
2020
- 2020-06-02 IL IL275076A patent/IL275076A/en unknown
-
2023
- 2023-09-21 JP JP2023156233A patent/JP2023179528A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112020011144A2 (pt) | 2020-11-17 |
IL275076A (en) | 2020-07-30 |
AU2018379091A1 (en) | 2020-06-25 |
MA51105A (fr) | 2020-10-14 |
EA202091407A1 (ru) | 2020-10-20 |
US20210207080A1 (en) | 2021-07-08 |
CN112041430A (zh) | 2020-12-04 |
KR20200108277A (ko) | 2020-09-17 |
JP2023179528A (ja) | 2023-12-19 |
JP2021505148A (ja) | 2021-02-18 |
CA3084444A1 (en) | 2019-06-13 |
WO2019113556A1 (en) | 2019-06-13 |
JP7433230B2 (ja) | 2024-02-19 |
SG11202005228YA (en) | 2020-07-29 |
EP3720949A1 (en) | 2020-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020005907A (es) | Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma. | |
MY201926A (en) | Biological methods for preparing terpenes | |
MX2017004890A (es) | Metodos y composiciones para la generación o el mantenimiento de células pluripotentes. | |
MX2016015004A (es) | Uso de moleculas pequeñas para mejorar la expresion de mafa en celulas endocrinas pancreaticas. | |
MX2021001859A (es) | Medio de cultivo celular libre de suero. | |
PH12018500130A1 (en) | Protein-rich biomass of thraustochytrids, culturing method, and uses | |
MY189051A (en) | Culture product of microorganism belonging to the genus wickerhamomyces | |
MX2015007361A (es) | Produccion mediada por la proteina portadora de acilo de los derivados de acidos grasos. | |
MX2016002468A (es) | Sistema y metodos para la propagacion continua y produccion en masa de hongos micorricicos arbusculares en cultivo liquido. | |
SG10201901559SA (en) | Retinal ganglion cells and progenitors thereof | |
EP4234032A3 (en) | Induction medium and methods for stem cell culture and therapy | |
WO2014200997A3 (en) | Method for preparing three-dimensional, organotypic cell cultures and uses thereof | |
PH12019550231A1 (en) | Probiotic bacteria preconditioned in a gos-containing medium and use thereof | |
MX2021001981A (es) | Metodos para preparar un poloxamero para usar en medio de cultivo celular. | |
WO2019204494A3 (en) | Date palm medium compositions and methods | |
EP4328299A3 (en) | Cell culture media compositions for primary cells | |
MY186581A (en) | Technology for efficient activation of nkt cells | |
WO2021101273A3 (ko) | 조절 t 세포 배양용 조성물 및 이의 용도 | |
MY194572A (en) | Self-sufficient process for the production of biomass hydrolysate with reduced salt content | |
SA117390093B1 (ar) | طريقة لإنتاج بناءات نانو سليلوز | |
UA101881U (ru) | Способ приготовления питательной среды для размножения мезенхимальных стволовых клеток человека и их производных | |
UA114767U (xx) | Спосіб одержання культури мезенхімально-стромальних клітин для подальшого їх культивування для терапевтичного застосування | |
WO2016022073A3 (en) | Bacterial strain | |
RU2013138890A (ru) | Технология производства вакцины лтф-130 | |
MY166513A (en) | Photobioreactor for cultivating spirulina |